These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 23226758)

  • 1. Relationship of α-fetoprotein levels and development of hepatocellular carcinoma in hepatitis C patients with liver cirrhosis.
    Taura N; Fukuda S; Ichikawa T; Miyaaki H; Shibata H; Honda T; Yamaguchi T; Kubota Y; Uchida S; Kamo Y; Yoshimura E; Isomoto H; Matsumoto T; Takeshima F; Tsutsumi T; Tsuruta S; Nakao K
    Exp Ther Med; 2012 Dec; 4(6):972-976. PubMed ID: 23226758
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alpha-fetoprotein above normal levels as a risk factor for the development of hepatocellular carcinoma in patients infected with hepatitis C virus.
    Tateyama M; Yatsuhashi H; Taura N; Motoyoshi Y; Nagaoka S; Yanagi K; Abiru S; Yano K; Komori A; Migita K; Nakamura M; Nagahama H; Sasaki Y; Miyakawa Y; Ishibashi H
    J Gastroenterol; 2011 Jan; 46(1):92-100. PubMed ID: 20711614
    [TBL] [Abstract][Full Text] [Related]  

  • 3. α-fetoprotein levels after interferon therapy and risk of hepatocarcinogenesis in chronic hepatitis C.
    Asahina Y; Tsuchiya K; Nishimura T; Muraoka M; Suzuki Y; Tamaki N; Yasui Y; Hosokawa T; Ueda K; Nakanishi H; Itakura J; Takahashi Y; Kurosaki M; Enomoto N; Nakagawa M; Kakinuma S; Watanabe M; Izumi N
    Hepatology; 2013 Oct; 58(4):1253-62. PubMed ID: 23564522
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
    Chen TM; Huang PT; Tsai MH; Lin LF; Liu CC; Ho KS; Siauw CP; Chao PL; Tung JN
    J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical implications of alpha-fetoprotein in chronic hepatitis C.
    Tai WC; Hu TH; Wang JH; Hung CH; Lu SN; Changchien CS; Lee CM
    J Formos Med Assoc; 2009 Mar; 108(3):210-8. PubMed ID: 19293036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A decrease in AFP level related to administration of interferon in patients with chronic hepatitis C and a high level of AFP.
    Murashima S; Tanaka M; Haramaki M; Yutani S; Nakashima Y; Harada K; Ide T; Kumashiro R; Sata M
    Dig Dis Sci; 2006 Apr; 51(4):808-12. PubMed ID: 16615008
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dynamic α-fetoprotein, platelets and AST-to-platelet ratio index predict hepatocellular carcinoma in chronic hepatitis C patients with sustained virological response after antiviral therapy.
    Wu CK; Chang KC; Hung CH; Tseng PL; Lu SN; Chen CH; Wang JH; Lee CM; Tsai MC; Lin MT; Yen YH; Hu TH
    J Antimicrob Chemother; 2016 Jul; 71(7):1943-7. PubMed ID: 27073265
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk factors for development of hepatocellular carcinoma in patients with chronic hepatitis C without sustained response to combination therapy.
    Chang KC; Ye YH; Wu CK; Lin MT; Tsai MC; Tseng PL; Hu TH
    J Formos Med Assoc; 2018 Nov; 117(11):1011-1018. PubMed ID: 29254684
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Utility of the FIB-4 Index for hepatocarcinogenesis in hepatitis C virus carriers with normal alanine aminotransferase levels.
    Ito T; Kumada T; Toyoda H; Tada T; Kiriyama S; Tanikawa M; Hisanaga Y; Kanamori A; Kitabatake S
    J Viral Hepat; 2015 Oct; 22(10):777-83. PubMed ID: 25608086
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alpha-fetoprotein before and after pegylated interferon therapy for predicting hepatocellular carcinoma development.
    Takeuchi Y; Ikeda F; Osawa T; Araki Y; Takaguchi K; Morimoto Y; Hashimoto N; Sakaguchi K; Sakata T; Ando M; Makino Y; Matsumura S; Takayama H; Seki H; Nanba S; Moritou Y; Yasunaka T; Ohnishi H; Takaki A; Nouso K; Iwasaki Y; Yamamoto K
    World J Hepatol; 2015 Sep; 7(19):2220-8. PubMed ID: 26380048
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Usefulness of serum alpha-fetoprotein (AFP) as a marker for hepatocellular carcinoma (HCC) in hepatitis C virus related cirrhosis: analysis of the factors influencing AFP elevation without HCC development].
    Kim KA; Lee JS; Jung ES; Kim JY; Bae WK; Kim NH; Moon YS
    Korean J Gastroenterol; 2006 Nov; 48(5):321-6. PubMed ID: 17132920
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic factors for survival in patients with compensated cirrhosis and small hepatocellular carcinoma after percutaneous ethanol injection therapy.
    Pompili M; Rapaccini GL; Covino M; Pignataro G; Caturelli E; Siena DA; Villani MR; Cedrone A; Gasbarrini G
    Cancer; 2001 Jul; 92(1):126-35. PubMed ID: 11443618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of inflammatory score/liver function and AFP improves the diagnostic accuracy of HBV-related hepatocellular carcinoma.
    Ding Y; Liu K; Xu Y; Zhao Q; Lou S; Xiang X; Yan L; Cao Z; Xie Q; Zhu C; Bao S; Wang H
    Cancer Med; 2020 May; 9(9):3057-3069. PubMed ID: 32150664
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Post-treatment levels of α-fetoprotein predict incidence of hepatocellular carcinoma after interferon therapy.
    Oze T; Hiramatsu N; Yakushijin T; Miyazaki M; Yamada A; Oshita M; Hagiwara H; Mita E; Ito T; Fukui H; Inui Y; Hijioka T; Inada M; Katayama K; Tamura S; Yoshihara H; Inoue A; Imai Y; Hayashi E; Kato M; Miyagi T; Yoshida Y; Tatsumi T; Kasahara A; Hamasaki T; Hayashi N; Takehara T;
    Clin Gastroenterol Hepatol; 2014 Jul; 12(7):1186-95. PubMed ID: 24321207
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved Performance of Serum Alpha-Fetoprotein for Hepatocellular Carcinoma Diagnosis in HCV Cirrhosis with Normal Alanine Transaminase.
    Yang JD; Dai J; Singal AG; Gopal P; Addissie BD; Nguyen MH; Befeler AS; Reddy KR; Schwartz M; Harnois DM; Yamada H; Gores GJ; Feng Z; Marrero JA; Roberts LR
    Cancer Epidemiol Biomarkers Prev; 2017 Jul; 26(7):1085-1092. PubMed ID: 28258053
    [No Abstract]   [Full Text] [Related]  

  • 16. Predictive value of tumor markers for hepatocarcinogenesis in patients with hepatitis C virus.
    Kumada T; Toyoda H; Kiriyama S; Tanikawa M; Hisanaga Y; Kanamori A; Tada T; Tanaka J; Yoshizawa H
    J Gastroenterol; 2011 Apr; 46(4):536-44. PubMed ID: 21132575
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determinants of serum alpha-fetoprotein levels in hepatitis C-infected patients.
    Richardson P; Duan Z; Kramer J; Davila JA; Tyson GL; El-Serag HB
    Clin Gastroenterol Hepatol; 2012 Apr; 10(4):428-33. PubMed ID: 22155556
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High Post-treatment α-Fetoprotein Levels and Aspartate Aminotransferase-to-Platelet Ratio Index Predict Hepatocellular Carcinoma in Hepatitis C Virus Decompensated Cirrhotic Patients with Sustained Virological Response After Antiviral Therapy.
    Ji F; Zhou R; Wang W; Bai D; He C; Cai Z; Shen Y; Wang S; Deng H; Li Z
    J Interferon Cytokine Res; 2017 Aug; 37(8):362-368. PubMed ID: 28731786
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatic steatosis is associated with increased frequency of hepatocellular carcinoma in patients with hepatitis C-related cirrhosis.
    Pekow JR; Bhan AK; Zheng H; Chung RT
    Cancer; 2007 Jun; 109(12):2490-6. PubMed ID: 17487861
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Validation of the AFP model as a predictor of HCC recurrence in patients with viral hepatitis-related cirrhosis who had received a liver transplant for HCC.
    Notarpaolo A; Layese R; Magistri P; Gambato M; Colledan M; Magini G; Miglioresi L; Vitale A; Vennarecci G; Ambrosio CD; Burra P; Di Benedetto F; Fagiuoli S; Colasanti M; Maria Ettorre G; Andreoli A; Cillo U; Laurent A; Katsahian S; Audureau E; Roudot-Thoraval F; Duvoux C
    J Hepatol; 2017 Mar; 66(3):552-559. PubMed ID: 27899297
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.